These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

755 related articles for article (PubMed ID: 30210004)

  • 1. Molecular Docking, G-QSAR Studies, Synthesis and Anticancer Screening of Some New 2-Phenazinamines as Bcr-Abl Tyrosine Kinase Inhibitors.
    Kale MA; Sonwane GM
    Curr Drug Discov Technol; 2020; 17(2):213-224. PubMed ID: 30210004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Searching for Potential Novel BCR-ABL Tyrosine Kinase Inhibitors Through G-QSAR and Docking Studies of Some Novel 2-Phenazinamine Derivatives.
    Kale M; Sonwane G; Choudhari Y
    Curr Comput Aided Drug Des; 2020; 16(5):501-510. PubMed ID: 30345925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive models for designing potent tyrosine kinase inhibitors in chronic myeloid leukemia for understanding its molecular mechanism of resistance by molecular docking and dynamics simulations.
    Melge AR; Kumar LG; K P; Nair SV; K M; C GM
    J Biomol Struct Dyn; 2019 Nov; 37(18):4747-4766. PubMed ID: 30580670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and biological evaluations of novel 3-amino-4-ethynyl indazole derivatives as Bcr-Abl kinase inhibitors with potent cellular antileukemic activity.
    El-Damasy AK; Jin H; Seo SH; Bang EK; Keum G
    Eur J Med Chem; 2020 Dec; 207():112710. PubMed ID: 32961435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-silico identification of inhibitors against mutated BCR-ABL protein of chronic myeloid leukemia: a virtual screening and molecular dynamics simulation study.
    Kumar H; Raj U; Gupta S; Varadwaj PK
    J Biomol Struct Dyn; 2016 Oct; 34(10):2171-83. PubMed ID: 26479578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a Predictive Pharmacophore Model and a 3D-QSAR Study for an in silico Screening of New Potent Bcr-Abl Kinase Inhibitors.
    Vrontaki E; Melagraki G; Voskou S; Phylactides MS; Mavromoustakos T; Kleanthous M; Afantitis A
    Mini Rev Med Chem; 2017; 17(3):188-204. PubMed ID: 28143387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis, Molecular Docking, Molecular Dynamics Studies, and Biological Evaluation of 4H-Chromone-1,2,3,4-tetrahydropyrimidine-5-carboxylate Derivatives as Potential Antileukemic Agents.
    Dolatkhah Z; Javanshir S; Sadr AS; Hosseini J; Sardari S
    J Chem Inf Model; 2017 Jun; 57(6):1246-1257. PubMed ID: 28524659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design,
    Koroleva EV; Ermolinskaya AL; Ignatovich ZV; Kornoushenko YV; Panibrat AV; Potkin VI; Andrianov AM
    Biochemistry (Mosc); 2024 Jun; 89(6):1094-1108. PubMed ID: 38981703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and biological evaluation of pyridin-3-yl pyrimidines as potent Bcr-Abl inhibitors.
    Pan X; Dong J; Gao H; Wang F; Zhang Y; Wang S; Zhang J
    Chem Biol Drug Des; 2014 May; 83(5):592-9. PubMed ID: 24330598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The First Pentacyclic Triterpenoid Gypsogenin Derivative Exhibiting Anti-ABL1 Kinase and Anti-chronic Myelogenous Leukemia Activities.
    Ciftci HI; Ozturk SE; Ali TFS; Radwan MO; Tateishi H; Koga R; Ocak Z; Can M; Otsuka M; Fujita M
    Biol Pharm Bull; 2018 Apr; 41(4):570-574. PubMed ID: 29386476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In silico design and computational evaluation of novel 2-arylaminopyrimidine-based compounds as potential multi-targeted protein kinase inhibitors: application for the native and mutant (T315I) Bcr-Abl tyrosine kinase.
    Koroleva EV; Kornoushenko YV; Karpenko AD; Bosko IP; Siniutsich JV; Ignatovich ZV; Andrianov AM
    J Biomol Struct Dyn; 2023 Jun; 41(9):4065-4080. PubMed ID: 35470777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and biological activity of phenyl-pyrazole derivatives as BCR-ABL kinase inhibitors.
    Hu L; Zheng Y; Li Z; Wang Y; Lv Y; Qin X; Zeng C
    Bioorg Med Chem; 2015 Jul; 23(13):3147-52. PubMed ID: 26022079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computer-aided drug design and virtual screening of targeted combinatorial libraries of mixed-ligand transition metal complexes of 2-butanone thiosemicarbazone.
    Khan T; Ahmad R; Azad I; Raza S; Joshi S; Khan AR
    Comput Biol Chem; 2018 Aug; 75():178-195. PubMed ID: 29883916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and biological activities of Nilotinib derivates as antitumor agents.
    Pan X; Wang F; Zhang Y; Gao H; Hu Z; Wang S; Zhang J
    Bioorg Med Chem; 2013 May; 21(9):2527-34. PubMed ID: 23538233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of novel Bcr-Abl
    Pan X; Liang L; Sun Y; Si R; Zhang Q; Wang J; Fu J; Zhang J; Zhang J
    Eur J Med Chem; 2019 Sep; 178():232-242. PubMed ID: 31185413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expanding the structural diversity of Bcr-Abl inhibitors: Dibenzoylpiperazin incorporated with 1H-indazol-3-amine.
    Shan Y; Dong J; Pan X; Zhang L; Zhang J; Dong Y; Wang M
    Eur J Med Chem; 2015 Nov; 104():139-47. PubMed ID: 26451772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of 2-Acylaminothiophene-3-Carboxamides as Multitarget Inhibitors for BCR-ABL Kinase and Microtubules.
    Cao R; Wang Y; Huang N
    J Chem Inf Model; 2015 Nov; 55(11):2435-42. PubMed ID: 26501568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, and biological activity of 4-(imidazo[1,2-b]pyridazin-3-yl)-1H-pyrazol-1-yl-phenylbenzamide derivatives as BCR-ABL kinase inhibitors.
    Hu L; Cao T; Lv Y; Ding Y; Yang L; Zhang Q; Guo M
    Bioorg Med Chem Lett; 2016 Dec; 26(23):5830-5835. PubMed ID: 28029512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. vHTS, 3-D Pharmacophore, QSAR and Molecular Docking Studies for the Identification of Phyto-derived ATP-Competitive Inhibitors of the BCR-ABL Kinase Domain.
    Metibemu DS; Oyeneyin OE; Metibemu AO; Adeniran OY; Omotuyi IO
    Curr Drug Discov Technol; 2022; 19(2):e021221198480. PubMed ID: 34856909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological difference between degrader and inhibitor against oncogenic BCR-ABL kinase.
    Shibata N; Shimokawa K; Nagai K; Ohoka N; Hattori T; Miyamoto N; Ujikawa O; Sameshima T; Nara H; Cho N; Naito M
    Sci Rep; 2018 Sep; 8(1):13549. PubMed ID: 30202081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.